Functional dyspepsia is a distressing, frequent disorder with a prevalence of approximately 15% in the general population. Anxiety was found to be strongly associated with new-onset functional dyspepsia. In addition, increased duodenal eosinophil counts have been observed in patients with functional dyspepsia. Gut symptoms may precede the development of anxiety in patients with a functional gut disorder. However, the underlying mechanisms are unknown. Duodenal eosinophilia is a potential cause of anxiety.
Population-based study from Sweden
From the national Swedish population register, 3,000 people were randomly selected. Subsequently, the participants were surveyed by the validated Abdominal Symptom Questionnaire (ASQ) and the Hospital Anxiety and Depression Scale (HADS). An oesophagogastroduodenoscopy was performed in 1,000 participants. All persons who were eligible from the latter cohort (n=887, response rate 79%), were invited to a follow-up with the ASQ and HADS. Functional dyspepsia was defined based on the Rome III. Anxiety and depression were defined by a score of ≥11 on the HADS.
In a nested case-control study, 89 patients with functional dyspepsia were compared with 124 healthy controls (mean age 62 years, 34% male). Duodenal histology was evaluated at baseline and divided into 2 groups, based on a pre-specified cut-off for the eosinophil count in the duodenal bulb:
- D1: cut-off of 23 eosinophils; and
- D2: cut-off of 24 eosinophils in the second part.
Duodenal eosinophilia was observed in 78 subjects in D1 and 84 subjects in D2 (in 46 subjects, both in D1 and in D2, P<0.001 for both) at baseline. Anxiety at baseline was found in 9 subjects (4%) and at follow-up in 12 subjects (6%).
After adjustment for age, gender, and functional dyspepsia status at baseline, the following associations between anxiety and duodenal eosinophilia were observed:
- Anxiety at baseline was independently associated with duodenal eosinophilia in D2 (P=0.013, OR=15.0), but not in D1 (P=0.2).
- Anxiety at follow-up was independently associated with duodenal eosinophilia in D1 at baseline (P=0.025, OR=5.90), but not D2 (P=0.5).
- Anxiety at follow-up was independently associated with functional dyspepsia at baseline (P=0.004, OR=7.42).
New-onset anxiety was more common in individuals meeting criteria for eosinophilia in D1 (7.5%) than those who did not meet the criteria (1.8%). The association was strong (OR=4.48), but failed to reach statistical significance (P=0.08). Hence, duodenal eosinophilia may be one mechanism by which anxiety arises in functional dyspepsia.
- Ronkainen J. Inter-relationships of duodenal eosinophilia, anxiety and functional dyspepsia. UEG Week Virtual Symposium 2020, abstract OP158.
Posted on
Previous Article
« Dupilumab improves in diverse aspects of eosinophilic oesophagitis Next Article
Filgotinib effective as maintenance treatment for ulcerative colitis »
« Dupilumab improves in diverse aspects of eosinophilic oesophagitis Next Article
Filgotinib effective as maintenance treatment for ulcerative colitis »
Table of Contents: UEGW 2020
Featured articles
Risk factors for severe COVID-19 among IBD patients
UEGW Round-Up Articles
Sustained efficacy of mirikizumab in moderate-to-severe Crohn’s disease
Low-FODMAPs diet does not improve PPI-refractory GERD
Probiotic provides a potential adjuvant treatment to gluten-free diet
Cholecystectomy does not affect mortality in elderly patients
No improvements of remission with etrolizumab in ulcerative colitis
Filgotinib effective as maintenance treatment for ulcerative colitis
Possible causal link between eosinophilic inflammation and anxiety
Dupilumab improves in diverse aspects of eosinophilic oesophagitis
Plecanatide effective for IBS with constipation
Sustained response to faecal microbiota transplantation
Endoscopy can be delivered safely during the COVID-19 pandemic
Adenoma detection rate improves over time
Post-colonoscopy colorectal cancers in IBD patients
Risk factors for severe COVID-19 among IBD patients
First randomised T2T trial using endoscopy to guide dose escalation
Related Articles
November 28, 2024
Moving towards the prevention of IBD
April 14, 2020
Ustekinumab in CD: a T2T trial
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com